Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Esperion Therapeutics Inc ESPR

Healthcare
Esperion Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol (LDL-C). The Company's products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company's NEXLETOL and NEXLIZET (bempedoic acid and ezetimibe) tablets are oral... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:ESPR)

Esperion to Report First Quarter 2024 Financial Results on May 7

GlobeNewswire 11 hours ago

Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity

GlobeNewswire April 7, 2024

Esperion to Ring Nasdaq Opening Bell Today, April 1, 2024

GlobeNewswire April 1, 2024

Esperion to Participate in 23rd Annual Needham Virtual Healthcare Conference

GlobeNewswire March 26, 2024

Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre to be Presented at ACC.24

GlobeNewswire March 25, 2024

U.S. FDA Approves Broad New Labels for Esperion's NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use

Business Wire March 22, 2024

U.S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use

GlobeNewswire March 22, 2024

CHMP Issues Positive Opinions For Both Bempedoic Acid And The Bempedoic Acid / Ezetimibe Fixed-Dose Combination Tablet As Treatments For Hypercholesterolemia And Significantly Reducing Cardiovascular Events

GlobeNewswire March 22, 2024

Esperion Reports Fourth Quarter and Full Year 2023 Financial Results

GlobeNewswire February 27, 2024
View More News ››

Opinion & Analysis (NDAQ:ESPR)

Topline Results from Lipid-Lowering Trial 'Just What the Doctor Ordered'

Streetwise Reports September 5, 2019

Biopharma Buys 'Insurance Policy Ahead of First Commercial Launch'

Streetwise Reports July 3, 2019
View More Opinion ››

Bullboard Posts (NDAQ:ESPR)

Esperion to Report First Quarter 2024 Financial Results on M

News; $ESPR Esperion to Report First Quarter 2024 Financial Results on May 7ANN ARBOR, Mich., April 23, 2024 (GLOBE NEWSWIRE...
whytestocks - 4 hours ago

Esperion Reports Fourth Quarter and Full Year 2023 Financial

Just In: $ESPR Esperion Reports Fourth Quarter and Full Year 2023 Financial Results@ FY23 U.S. Net Product Revenue Grew 40% Y/Y to $78.3...
whytestocks - February 27, 2024

Esperion Announces Submission of Supplemental New Drug Appli

JUST IN: $ESPR Esperion Announces Submission of Supplemental New Drug Applications to U.S. FDA for NEXLETOL&#xAE; (bempedoic acid...
whytestocks - June 1, 2023

When will judge make decision

Agreement should be clear re milestones 
edrose - March 23, 2023

It lowers ldl but bigger question does it decrease

Heart attacks, and mortality  
edrose - March 9, 2023

ESPR Corporate and Financial Update

Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports First Quarter Financial Results For the full news...
BearDownAZ - May 9, 2019
View more Bullboard ››

Nanalysis Scientific Corp.

Nanalysis Scientific Corp.

Nanalysis develops and manufactures compact MRI and NMR devices for clinical, laboratory, and industrial markets. These ...
View More »